TriSalus Life SciencesNASDAQ: TLSI

Profile

Sector:

Healthcare

Country:

United States

IPO:

08 February 2021

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$117.54 M
-61%vs. 3y high
46%vs. sector
-vs. 3y high
-vs. sector
-116%vs. 3y high
6%vs. sector
-76%vs. 3y high
59%vs. sector

Price

regular market | Fri, 01 Nov 2024 20:00:00 GMT
$4.01+$0.04(+1.01%)

Dividend

No data over the past 3 years
$7.36 M$7.39 M
$7.36 M-$4.33 M

Analysts recommendations

Institutional Ownership

TLSI Latest News

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
https://www.businesswire.com/news/home/20241014472226/en/TriSalus-Life-Sciences-to-Participate-in-the-2024-Maxim-Healthcare-Virtual-Summit/14 October 2024 Sentiment: POSITIVE

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today that Mary Szela, Chief Executive Officer and President of TriSalus, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024. Details for the fireside ch.

TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript
seekingalpha.com15 August 2024 Sentiment: NEUTRAL

TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2024 Earnings Call Transcript August 15, 2024 9:00 AM ET Company Participants Jim Young - SVP, IR and Treasurer Mary Szela - President and CEO Alex Kim - SVP, Interventional Radiology Steven Katz - CMO Sean Murphy - CFO Conference Call Participants Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science Second Quarter 2024 Earnings Conference Call. Currently, all participants are on listen-only mode.

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
businesswire.com26 June 2024 Sentiment: POSITIVE

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the expiration and results of its previously announced exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Ex.

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
businesswire.com24 May 2024 Sentiment: POSITIVE

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Exchange (as defined below). The purpose of.

TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript
Seeking Alpha15 May 2024 Sentiment: POSITIVE

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) will hold its Q1 2024 Earnings Conference Call on May 15, 2024 at 9:00 AM ET. Participants include Jim Young, Mary Szela, Sean Murphy, and Justin Walsh from JonesTrading. Good morning and welcome to the TriSalus Life Sciences First Quarter 2024 Earnings Conference Call.

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
Business Wire06 May 2024 Sentiment: POSITIVE

TriSalus Life Sciences® Inc., an oncology company combining its unique delivery technology with immunotherapy to revolutionize treatment for patients with liver and pancreatic tumors, will hold a conference call and webcast on May 15, 2024, at 9:00 a.m. ET to review financial results for the first quarter ending March 31, 2024, and offer a business update. A press release with the first quarter results will be released beforehand.

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
Business Wire11 March 2024 Sentiment: NEGATIVE

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will host a conference call and webcast on April 1, 2024, at 9:00 a.m. ET to discuss financial results for the fourth quarter and full year ended December 31, 2023, and provide a business update. A press release detailing the fourth quarter and full year results will be issued prior to the call. Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Results Full financial results fo.

What type of business is TriSalus Life Sciences?

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

What sector is TriSalus Life Sciences in?

TriSalus Life Sciences is in the Healthcare sector

What industry is TriSalus Life Sciences in?

TriSalus Life Sciences is in the Medical Devices industry

What country is TriSalus Life Sciences from?

TriSalus Life Sciences is headquartered in United States

When did TriSalus Life Sciences go public?

TriSalus Life Sciences initial public offering (IPO) was on 08 February 2021

What is TriSalus Life Sciences website?

https://trisaluslifesci.com

Is TriSalus Life Sciences in the S&P 500?

No, TriSalus Life Sciences is not included in the S&P 500 index

Is TriSalus Life Sciences in the NASDAQ 100?

No, TriSalus Life Sciences is not included in the NASDAQ 100 index

Is TriSalus Life Sciences in the Dow Jones?

No, TriSalus Life Sciences is not included in the Dow Jones index

When was TriSalus Life Sciences the previous earnings report?

No data

When does TriSalus Life Sciences earnings report?

The next expected earnings date for TriSalus Life Sciences is 14 November 2024